Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
<h4>Background</h4> <p>The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 stu...
Հիմնական հեղինակներ: | Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E |
---|---|
Ձևաչափ: | Journal article |
Հրապարակվել է: |
BioMed Central
2018
|
Նմանատիպ նյութեր
-
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
: Philip Helliwell, և այլն
Հրապարակվել է: (2018-10-01) -
Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
: Helliwell, P, և այլն
Հրապարակվել է: (2018) -
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
: Nash, P, և այլն
Հրապարակվել է: (2018) -
Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
: Nash, P, և այլն
Հրապարակվել է: (2018) -
Janus kinase inhibitors in the treatment of psoriatic arthritis
: E. Yu. Loginova, և այլն
Հրապարակվել է: (2022-02-01)